Evaxion A (EVAX) Non-Current Assets (2019 - 2025)
Evaxion A's (EVAX) quarterly Non-Current Assets came in at $3.5 million in Q4 2025, down 5.73% YoY from $3.7 million in Q4 2024, and down 17.91% on a QoQ basis from $4.3 million in Q2 2025.
Evaxion A (EVAX) Non-Current Assets (2019 - 2025) Analysis & Trends
Evaxion A (EVAX) has 7 years of Non-Current Assets data on file, last reported at $3.5 million in Q4 2025.
- Quarterly Non-Current Assets fell 5.73% year-over-year to $3.5 million in Q4 2025, while the trailing twelve-month figure through Jun 2025 was $4.3 million (down 5.72% YoY) and the FY2025 annual result came in at $3.5 million, down 5.73% from the prior year.
- Non-Current Assets fell to $3.5 million in Q4 2025, from $4.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $7.8 million in Q3 2021 to a low of $2.4 million in Q1 2021.
- A 5-year average of $4.8 million and a median of $4.5 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets jumped 437.73% — and 2024, when it retreated 18.04%.
- Tracing EVAX's Non-Current Assets over 5 years: stood at $5.5 million in 2021, then declined by 7.66% to $5.0 million in 2022, then retreated by 9.94% to $4.5 million in 2023, then dropped by 18.04% to $3.7 million in 2024, then fell by 5.73% to $3.5 million in 2025.
- The last three Non-Current Assets figures came in at $3.5 million (Q4 2025), $4.3 million (Q2 2025), and $3.7 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 18.06 Bn |
| 10 | Evaxion A | 27.52 Mn | 27.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.51 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Dec 31, 2024 | 3.72 Mn |
| Jun 30, 2024 | 4.53 Mn |
| Dec 31, 2023 | 4.54 Mn |
| Jun 30, 2023 | 5.39 Mn |
| Dec 31, 2022 | 5.04 Mn |
| Jun 30, 2022 | 5.48 Mn |
| Mar 31, 2022 | 5.70 Mn |
| Dec 31, 2021 | 5.46 Mn |
| Sep 30, 2021 | 7.80 Mn |
| Jun 30, 2021 | 4.23 Mn |
| Mar 31, 2021 | 2.43 Mn |
| Dec 31, 2020 | 1.02 Mn |
| Dec 31, 2019 | 126,000.00 |